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IMMUNITY totransplantedtumours inanimals has beenextensivelyinvestigated
although failure to control genetic factors rendered much of the earlier work of
doubtful value. Following the criticisms of Woglom (1929), greater attention was
paid to experimental design particularly with regard to the host-tumour relation-
ship and in a number of studies, immunity has been produced against tumours
which arose in, and grew progressively in inbred strains of animals (Hauschka,
1952; Stern, 1953). In a series ofstudies reported by Aptekman, Lewis and King
(1946, 1949) and by Lewis, King, Aptekman and Seibert (1948), immunity to
transplanted tumours in inbred rats was induced following destruction ofgrowing
tumours by injecting them with ethanol extracts ofhomologous tumour tissue and
by pre-treating tumour-susceptible rats with the tumour extracts. The tumours
used in these studies were induced in inbred strains of rats and were transplanted
into animals of the same strains. In most cases, however, the tumours had been
repeatedly sub-passaged and it was suggested by Hauschka (1952) that this
repeated transplantation may have produced immunogenetic differences between
tumour and host strain ofanimals which would favour a refractory state following
tumour destruction.
In the following experiments, the effect of tumour extracts on tumour growth
has been studied using methylcholanthrene-irnduced tumours in inbred rats.
Initially, these tumours had not been through many transplant generations so
that any effect due to repeated tumour transplantation would be minimized.
Experiments were also performed using tumours which had been sub-passaged
through known numbers ofgenerations so that any effect due to repeated tumour
transplantation could be determined.
MATERIALS AND METHODS.
Animals and tumours.
Experiments were performed with inbred rats ofa Wistar strain. A number of
litters ofthis inbred strain were obtained from Boots Pure Drug Co., Ltd., Notting-
ham, and tumours were induced in one rat of each litter following a single subcu-
taneous injection of methylcholanthrene. Each tumour grew progressively on
implantation into the offspring produced by mating the litter mates of the
tumour donor rat although the growth rate of the different tumours varied
considerably. The tumours were designated as follows:
Tumour S69 (Group I).-A highly cellular anaplastic sarcoma which grew
rapidly so that host rats had to be killed within 10 to 14 days.EFFECT OF TUMOUR EXTRACTS ON HOMOLOGOUS TUMOURS
Tumour S5 (Group B).-A moderately cellular fibrosarcoma which grew
fairly rapidly, reaching palpable size in 4 to 5 days. Rats bearing this tumour had
to be killed within 3 to 4 weeks.
Tumour S66 (Group JII).-A moderately cellular sarcoma showing some
differentiation into fibrous tissue. Implants of this tumour reached palpable size
within 9 to 12 days and grew fairly slowly so that host rats had to be killed within
5 to 7 weeks.
Tumour implants were made subcutaneously in the right dorsal region using
a No. 15 gauge trocar and cannula. The tumour tissue used at each transplant
was obtained under sterile conditions from the healthy peripheral part of a single
tumour, and was sectioned into small pieces just large enough to fit into the trocar.
The tumour graft in all cases consisted of approximately one half trocar full of
tumour tissue.
Preparation of tumour extracts.
Rats bearing tumours of a suitable size were killed by fracture of the spinal
,cord and the tumours were quickly removed to ice-cooled containers. The tumour
tissue was pooled after the removal of any necrotic tissue and homogenised in an
ice-cooled, vertical, top drive, homogeniser. The tumour homogenate was mixed
with an equal amount of 95 per cent ethanol (1 ml. per gram of tumour), allowed
to stand at 40 C. for 24 hours and then treated with a further two volumes of
ethanol. This facilitated the separation ofthe tumour residue which was removed
by centrifugation (3000 r.p.m. and 00 C.). The final tumour extracts were pale
yellow in colour with an ethanol content of 75 to 80 per cent. These extracts were
concentrated at 30-34° C. under reduced pressure to one-tenth of their original
volume.
The concentrated ethanol extracts contained considerable amounts of white
insoluble material. No attempt was made to separate this insoluble material or
to adjust the ethanol concentration of the tumour extracts used in the treatment
of tumours. Dry weight determinations at 1100 C. indicated that the extracts
contained amounts of total solids varying between 40 and 70 milligrams per
millilitre.
Experimental procedure.
Experiments were performed using whole litters of rats, and in each case a
number of implanted rats were left untreated to serve as controls. Rats bearing
tumour implants which had grown from 4 to 12 days (depending upon the tumour
used) and had reached a size of approximately 20 x 10 x 10 mm. were treated
with the appropriate tumour extract concentrate. Injections were made directly
into the tumours, each rat receiving 0*5 or 1*0 ml. of the extract daily until the
tumour regressed or until it became evident that tumour growth would continue
and the rats were killed. Rats in which tumours had regressed following treatment
were tested for immunity 3 to 4 weeks after the original implantation site had
healed. Challenge grafts which were made in the left flank were approximately
one-half the size of the original graft. Rats in which the challenge graft failed to
grow were re-implanted one month later with large amounts of tumour (two or
three trocars full) and kept under observation for at least six months.
Attempts were also made to induce tumour immunity by pre-treating rats with
the tumour extract concentrates. In these experiments, rats of several litters.
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were injected subcutaneously with the appropriate tumour extract. Each rat
received a total of 4-5 ml. oftumour extract concentrate in doses of 05 ml. over a
period of three weeks. Three weeks after the last injection, the treated rats
together with a number of untreated-litter mates as controls were implanted with
challenge grafts of the appropriate tumour.
RESULTS.
The results of treating growing tumours by injecting them with ethanol
extract concentrates ofhomologous tumour tissue are shown in Table I. Consider-
able damage was caused in tumours treated with the tumour extracts and they
became blackened and dry. This damage was often brought about by as few as 3
to 5 injections ofthe tumour extracts and in a number ofexperiments the damaged
tumours regressed, leaving a well-healed scar at the site ofimplantation. Usually,
however, treated tumours continued to grow, even though treatment with the
extracts was continued, until eventually the rats had to be killed. Altogether 104
rats bearing implants of 3 different tumours were treated with tumour extract
concentrates prepared from 13 different collections of tumour tissue, and out of
these only 5 tumours regressed completely. In a number of experiments further
tumour growth was observed 2 to 4 weeks after the original tumour implant had
TABLE L.-Results of Treating Transplanted Tumours with Homologous
Tumour Extract Concentrates.
Total
Tumour volume Number of
Tumour and Transplant extract of concentrate Number of Number of untreated
litter of generation concentrate injected animals tumours animals
origin. treated. injected.* (ml.). treated. regressing. inoculated.t
S5 . 8.. 6 S5 . 20 . 2 . 0 . 3
(Group B)* 9 8 S5 . 11 . 10 * 0 . 5
11 . 9 S5 . 20 . 11 . 0 . 5
14 . 11S5 . 26 . 12 . 1 4
19 . 13 S5 . 19 . 8 . 0 . 6
20 . 18 S5 . 14 . 5 . 0 . 8
Total . . . . 48 . 1 . 31
S69 . 3 . 1S69 . 12 . 6 . 0 . 3
(Group I) 4 . 1S69 . 16 . 3 . 0 . 3
15 . 2 S69 . 23 . 5 . 1 . 3
16 . 5 S69 14 . 12 . 0 . 4
Total . - . - 26 . 1 . 13
S66
(Group III) 3 . 1S66 . 46 7 . 0 . 5
a . 3 S66 . 30 . 6 . 0 . 3
6 . 4 S66 . 20 6 . 0 . 3
9 . 7 S66 . 18 . 11 . 3 . 6
Total . - . - - . 30 . 3 . 17
Total . . . 104 . 5 . 61
* Figures indicate the transplant generation of tumour used for the preparation of the tumour
extracts.
t Tumour grew in all untreated animals.EFFECT OF TUMOUR EXTRACTS ON HOMOLOGOUS TUMOURS
regressed following treatment. None of the recurrent tumour growths regressed
following further treatment with tumour extract. The 5 rats in which tumours
had regressed completely were re-implanted several times over a six-month period
with large amounts ofthe appropriate tumour and all remained immune to tumour
growth.
The experiments summarised in Table II show that pre-treatment of tumour-
susceptible rats with tumour extract concentrate was ineffective in producing
tumour immunity. Thus none of the 47 rats pre-treated with the appropriate
tumour extract proved to be immune upon implantation with the homologous
tumour and the tumour grafts grew as rapidly as the implants in untreated
control animals.
TABLE II.-The Effect of Prior Injections of Tumour Extract Concentrates on the
Growth of Implants of the Homologous Tumours.
Tumour and Tumour extract Number resistant Number of
litter of concentrate Number of rats to growth of untreated animals
origin. injected.* treated. tumour implants. inoculated.t
S5 . 19 S5 . 8 0 . 6
(Group B) 26 S5 . 12 . 0 . 3
S66 . 8 S66 12 . 0 . 3
(Group III) . 12 S66 . 15 . 0 . 3
Total . . . 47 . 0 . 15
* Figures indicate the transplant generation of tumour used for the preparation of the tumour
extracts.
t Tumour grew in all untreated animals.
DISCUSSION.
In most cases where immunity has been induced against tumours which origi-
nated in inbred strains of animals, the tumours had been repeatedly sub-passaged
over long periods oftime. It is now generally agreed that mutation oftumour may
occur during such procedures resulting in the development of immunogenetic
differences between tumour and host which facilitate the development of tumour
immunity. The tumours used in the present experiments were induced in highly
inbred rats and had been sub-passaged only a few times, so that the chance of
tumour mutation was miimised. Attempts to induceregression of these tumours
by treating them with ethanol extracts of homologous tumour tissue were nearly
always unsuccessful and no difference was noted in the response to treatment of
implants ofthe different tumours between the 3rd and 20th generation oftransfer
(Table I). Similarly treatment ofrats with the tumour extracts failed to alter their
susceptibility to tumour growth and tumour grafts grew in all treated animals.
These results fail to confirm the findings of Aptekman, Lewis and King (1946,
1949), although they are in agreement with the results of recent studies, where
attempts to repeat earlier work using tumours which arose spontaneously in inbred
animals and hadbeen sub-passaged in animals oftheir strain oforiginthrough only
a few transplant generations were completely unsuccessful (Fardon and Prince,
1953,; Foley, 1953; Goldfeder, 1954). Thus Goldfeder showed that tumour
resistance could be induced in inbred rats (Bagg strain) following regression of
X-irradiated grafts of an autogenous tumour. Although this tumour arose in a
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rat ofthe Bagg strain, it had reached its 75th generation oftransfer at the time of
the experiment. Attempts to repeat this work using three highly inbred strains
ofmice (C57BL, C3H and DBA) and two inbred strains ofrats (A x C and August)
and with tumours originating in these inbred strains have been unsuccessful
(Goldfeder, 1953; 1954).
Thepossibilitythat the tumour extracts used inthe present study were inactive
cannot be ruled out, although this is unlikely since the extracts were prepared
under conditions similar to those used by Lewis, King, Aptekman and Seibert
(1948). In addition, the tumour extract concentrates usually caused considerable
damage to tumours, especially in the earlier stages oftreatment. In almost every
case, however, the damaged tumours continued to grow even though treatment
with the tumour extracts was continued.
Inthe studies ofAptekman, Lewis andKing (1946)practicallyallofthe tumours
treated with ethanol extracts of homologous tumour tissue regressed leaving the
curedratsresistant tofurtherimplants oftheoriginal tumour. It was alsoobserved,
however, that tumour regression and immunity could be induced using ethanol
extracts of non-related human tumour tissue. These results suggest that some
other factor, probably depending upon antigenic differences between tumour and
host strain of animals, is responsible for the induction of tumour immunity
following tumour destruction by some " toxic " agent in the tumour extracts.
This would explain the failure of the present experiments since the tumours used
had been sub-passaged only a few times so that the chance of tumour mutation
was minimized. Under these circumstances immunogenetic differences between
tumour andhost may not have existed, or morelikely not have been great enough
to elicit an immune response sufficient to permit the development of tumour
immunity.
The nature of the tumour destroying substance in the tumour extracts is still
unknown, although comparative studies of the chemical composition of ethanol
extracts ofmalignant andnormalanimaltissue have revealed significant differences
in the concentration of many of the known constituents, including carbohydrate
andbound andfree amino acids. (Seibert, Soto-Figueroa, Miller, Seibert, Aptekman
and Lewis, 1954; Seibert, Soto-Figueroa, Miller and Seibert, 1954). It was
suggested by Hauschka (1952), in reference to the work of Aptekman, Lewis and
King (1946), that lipid or lipoprotein antigens may be involved in the production
of tumour regression and immunity by means of ethanol extracts of tumour
tissue. However, this suggestion could not be substantiated since little or no lipid
material was detected in the tumour extracts. Perrault and Shear (1955) have
isolated polysaccharide-containing fractions from a number of animal tumours
with biological properties similar to those of certain bacterial polysaccharides.
These fractions were shown to induce haemorrhagic necrosis in tumours following
intraperitoneal injection into tumour--bearing animals and they also inhibited
growth of several animal tumours. It is possible that the tumour destroying and
toxic activity of ethanol extracts of rat tumour tissue may depend upon the
presence of similar polysaccharides.
SUMMARY.
Rats bearing grafts of tumours originally induced within the same inbred
strain ofanimals were treated with ethanol extract concentrates ofthe homologous
tumours. The tumour extracts caused considerable tissue destruction when
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injected into growing tumors, although only a few ofthe treated tumours regressed
completely. Where treated tumours regressed and the hosts remained free from
recurrent growth ofthe original graft, the hosts were foundto beimmune to further
implants ofthe same tumour. Treatment ofrats with the tumour extract concen-
tratespriortoimplantation oftumourfailedtoinduceanyimmunityandthetumour
grafts grew as rapidly as those in untreated animals.
It is suggested that the development of tumour immunity depends upon the
presence of immunogenetic differences in the tumour-host relationship and that
the ethanol extracts of tumour tissue act as tumour destroying agents which
inhibit tumour growth and so permit the development of immune processes.
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